Clinical trial for Ovarian Cancer
Official title HRD Tests for Ovarian cancER
ClinicalTrials.gov ID: NCT06152731
What this study is testing
What is tests to determine HRD status?
tests to determine HRD status is an investigational medicine, being studied as a potential treatment for ovarian cancer.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study concerns patients with Invasive epithelial ovarian cancer, primary Fallopian tube carcinoma, ovarian-type peritoneal carcinoma, and with an indication of a first-line platinum-based chemotherapy.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older, women only
You may be able to join if
- Patient aged 18-year or more
- Histologically documented high grade serous epithelial ovarian cancer, fallopian tube or peritoneum cancer
- Newly diagnosed advanced (International Federation of Gynecology and Obstetrics [FIGO] stage III or IV) ovarian carcinoma, candidate to a first line...
- Tumor tissue must be available for HRD analyses (FFPE tissue block) and
- Collected if possible during the initial surgery or the initial biopsy (before chemotherapy)
You likely can't join if
- Recurrent high grade serous epithelial ovarian cancer, fallopian tube or peritoneum cancer
- Non epithelial or borderline ovarian cancer
- Other tumor, for which the treatment may interfere with the ovarian cancer treatment and/or that may have a major impact on prognosis
- Exclusive palliative setting
- Patient deprived of liberty or placed under the authority of a tutor
See the full eligibility criteria
- Patient aged 18-year or more
- Histologically documented high grade serous epithelial ovarian cancer, fallopian tube or peritoneum cancer
- Newly diagnosed advanced (International Federation of Gynecology and Obstetrics [FIGO] stage III or IV) ovarian carcinoma, candidate to a first line platinum-based chemotherapy
- Tumor tissue must be available for HRD analyses (FFPE tissue block) and
- Collected if possible during the initial surgery or the initial biopsy (before chemotherapy)
- With sufficient tumour surface area (\> 25 mm²), with a final cellularity of at least 20%
- Patient affiliated to an appropriate social security system
- Patient signed consent form before any trial related activities
- Recurrent high grade serous epithelial ovarian cancer, fallopian tube or peritoneum cancer
- Non epithelial or borderline ovarian cancer
- Other tumor, for which the treatment may interfere with the ovarian cancer treatment and/or that may have a major impact on prognosis
- Exclusive palliative setting
- Patient deprived of liberty or placed under the authority of a tutor
The study team makes the final eligibility decision.
Where it is enrolling
- Caen, France
- Lille, France
- Rouen, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Caen, France; Lille, France; Rouen, France. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.